Systemic Radiotherapy With Monoclonal Antibodies: Options and Problems (Recent Results in Cancer Research)

Sautter-Bihl, Marie-Luise

ISBN 10: 364279954X / ISBN 13: 9783642799549

Published by Springer Berlin Heidelberg, 2012

About this Item

reprint edition. 207 pages. 9.25x6.10x0.05 inches. In Stock.

Seller Inventory # x-364279954X

Bibliographic Details

• Title: Systemic Radiotherapy With Monoclonal Antibodies: Options and Problems (Recent Results in Cancer Research)
• Publisher: Springer Berlin Heidelberg
• Publication Date: 2012
• Language: English
• ISBN 10: 364279954X
• ISBN 13: 9783642799549
• Binding: Paperback
• Condition: Brand New
• Weight: 0.3 kilograms

About this title

Synopsis

Almost a century ago Paul Ehrlich introduced the "magic bullet" concept of targeting therapeutic agents to specific tissues in order to reduce systemic toxicity. Due to the advances in hybridoma technology in the 1980s, monoclonal antibodies (MAbs) with their exquisite affinity to tumor antigens have become powerful tools in the treatment of cancer, especially when linked to therapeutic agents such as radionuclides, drugs, toxins, or enzymes. It can now be expected that such agents will lead to new cancer treatments with high therapeutic success rates. However, there are major problems in developing this therapeutic concept to a routine treatment modality. This is partly due to factors such as heterogenous distribution of tumor antigens, insufficient blood supply of tumors, high interstitial pressure, and the large interstitial space that antibodies have to traverse. This book is focused on the development in radio immunotherapy (RIT) using radio­ labeled monoclonal antibodies as tumoritoxic agents. This area of research has attracted the interest of clinicians and scientists from many different disciplines. It is now clear that the full potential of RIT can only be realized through the concerted efforts of laboratory scientists (molecular biologists, cell physiologists, chemists, radiation physicists, and biologists) and cancer clinicians in nuclear medicine, radiooncology, and internal oncology.

Review

"a timely and deliberately provocative new impetus to this long overdue discussion of promising, selective cancer treatment." Jnl. of the National Cancer Institute